Voyager Therapeutics (NASDAQ:VYGR) Stock Breaks Below 50 Day Moving Average - Here's Why

Key Points

• Voyager Therapeutics shares fell below their 50-day moving average, trading as low as $2.02 before closing at $2.19, compared with a 50-day average of $2.95.
• Analyst sentiment remains mixed but leans positive, with a consensus rating of “Moderate Buy” and an average price target of $16.50; ratings include one Strong Buy, two Buys, and one Sell.
• The company remains financially challenged, reporting a quarterly loss of $0.40 per share, $3.17 million in revenue, and a negative net margin of 312.63%, while institutional investors own 48.03% of the stock.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report)'s share price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $2.95 and traded as low as $2.02. Voyager Therapeutics shares last traded at $2.19, with a volume of 1,114,228 shares changing hands.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Voyager Therapeutics in a report on Friday, October 9th. HC Wainwright reiterated a "buy" rating on shares of Voyager Therapeutics in a research report on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Voyager Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $16.50.

Voyager Therapeutics Stock Up 6.8%

The company has a market cap of $134.94 million, a price-to-earnings ratio of -1.22 and a beta of 1.28. The firm has a 50 day moving average price of $2.95 and a two-hundred day moving average price of $3.38.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.08. The business had revenue of $3.17 million for the quarter, compared to analysts' expectations of $4.52 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. On average, equities analysts expect that Voyager Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

Several large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Voyager Therapeutics during the 2nd quarter worth approximately $18,102,000. Renaissance Technologies LLC increased its stake in shares of Voyager Therapeutics by 95.0% in the 1st quarter. Renaissance Technologies LLC now owns 578,024 shares of the company's stock valued at $2,231,000 after acquiring an additional 281,574 shares in the last quarter. Deutsche Bank AG acquired a new position in shares of Voyager Therapeutics during the 2nd quarter valued at $180,000. Bank of New York Mellon Corp acquired a new position in shares of Voyager Therapeutics during the 2nd quarter valued at $513,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Voyager Therapeutics during the 2nd quarter valued at $122,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company uses its proprietary TRACER capsid discovery platform to identify adeno-associated virus (AAV) capsids designed to improve the delivery of genetic medicines to the brain and central nervous system.

Voyager's research and development programs have addressed conditions including Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis and Friedreich's ataxia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.